Bleomycin a2

Base Information

• Chemical Name: Bleomycin a2
• CAS No.: 9041-93-4
• Deprecated CAS: 1247874-09-4,69215-21-0,754126-85-7
• Molecular Weight: 2927.17
• Hs Code.: 2941906000
• European Community (EC) Number: 232-925-2,234-356-5,689-127-6
• DSSTox Substance ID: DTXSID20872327
• Nikkaji Number: J25.633A
• Wikipedia: Bleomycin
• Wikidata: Q26841044
• NCI Thesaurus Code: C311,C313,C312
• RXCUI: 1621,1622
• Metabolomics Workbench ID: 133738
• ChEMBL ID: CHEMBL403664
• Mol file: 9041-93-4.mol

Synonyms:Bellon, Bléomycine;Bléomycine Bellon;Blanoxan;Blenoxane;BLEO cell;BLEO-cell;BLEOcell;Bleolem;Bleomicina;Bleomycin;Bleomycin A(2);Bleomycin A2;Bleomycin B(2);Bleomycin B2;Bleomycin Sulfate;Bleomycins;Bleomycinum Mack;Mack, Bleomycinum;Sulfate, Bleomycin

Chemical Property of Bleomycin a2

Chemical Property:

• Appearance/Colour: white powder
• Melting Point: 197oC (dec)
• PSA: 1506.34000
• LogP: -4.20880
• Storage Temp.: 2-8°C
• Solubility.: H2O: 20 mg/mL
• Water Solubility.: Soluble in water or DMSO
• XLogP3: -7.5
• Hydrogen Bond Donor Count: 20
• Hydrogen Bond Acceptor Count: 31
• Rotatable Bond Count: 36
• Exact Mass: 1414.51898128
• Heavy Atom Count: 96
• Complexity: 2580

Purity/Quality:

98%min ^*data from raw suppliers

Bleomycin Sulfate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T,Xi
• Hazard Codes: T,Xi
• Statements: 46-40-36/37/38-63
• Safety Statements: 53-36/37-45-36-26

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Isomeric SMILES: CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
• Recent ClinicalTrials: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
• Recent EU Clinical Trials: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic cancer' (IREC).
• Recent NIPH Clinical Trials: International Clinical Trial of Low and Standard Risk Germ Cell Tumors; AGCT1531
• Description: Bleomycin sulfate (9041-93-4) coordinates with metals producing reactive oxygen species which causes oxidative damage to DNA1?and RNA2. Induces double-strand DNA damage.3?Commonly used to induce lung fibrosis in animal disease models.4,5?Anticancer agent in clinical use.6
• Uses: A group of related glycopeptide antibiotics. Bleomycin A2 is the main component of the bleomycin employed clinically. Antineoplastic Bleomycin is a complex of 11 glycopeptide antitumour antibiotics originally isolated from Streptomyces verticillus in 1972. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight . Bleomycins have found clinical application in the treatment of a range of tumours. Bleomycins act by intercalation of DNA and RNA. In the presence of oxygen and metal ions, notably copper and iron, bleomycins form a pseudo-enzyme that induces DNA cleavage. Bleomycin is a complex of 11 glycopeptide antitumor antibiotics originally isolated from Streptomyces verticillus in 1972. The dominant components of the complex are bleomycin A2 and B2, which typically represent >90% of the total weight. Bleomycins have found clinical application in the treatment of a range of tumors. Bleomycins act by intercalation of DNA and RNA. In the presence of oxygen and metal ions, notably copper and iron, bleomycins form a pseudo-enzyme that induces DNA cleavage. Bleomycin sulfate binds to DNA, and can inhibit DNA synthesis and causes scission of DNA. Cleaves DNA, requires binding to oxygen and a metal ion, such as copper or iron. Able to cleave RNA, but at less and more selective degree. Also reported to induce and regulate apoptosis in a variety of cells, and inhibit tumor angiogenesis.
• Clinical Use: Bleomycin is used IV in the palliative treatment of squamous cell head and neck cancers, testicular and other genital carcinomas, and Hodgkin's and non-Hodgkin's lymphoma.

Technology Process of Bleomycin a2

There total 1 articles about Bleomycin a2 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ bleomycin (11056-06-7,9041-93-4)

Guidance literature:

Refernces

• 1、 -. "Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same". . . Retrieved 2010/05/13.
• 2、 -. "Compositions containing piperine". . . Retrieved 2008/06/13.